department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Epidiolex · pharmadog

pharmadog
drugs
Epidiolex

drug · small molecule

patient view →

cannabidiol

Marketedupdated 2mo ago

by $JAZZ Jazz Pharmaceuticals plc🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 82 investigational indications.

indications

investigational

EpilepsySchizophrenia

targets

Cannabinoid receptor 1

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Epidiolex

trade names

Epidiolex, Epidyolex

generic

cannabidiol

MOA

Cannabinoid CB1 receptor negative allosteric modulator

indication

Infantile Spasm (West Syndrome)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 20, 2026

105 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (32)

Mar 1, 2041method-of-use (U-3233)US 11160795
Mar 1, 2041method-of-use (U-3233)US 11406623
Mar 1, 2041method-of-use (U-3233)US 12102619
Apr 26, 2039compositionUS 11207292
Apr 26, 2039compositionUS 11865102
Oct 13, 2035method-of-use (U-3073)US 10918608
Oct 13, 2035method-of-use (U-3071)US 11065209
Oct 13, 2035compositionUS 11096905
Oct 13, 2035method-of-use (U-3071)US 11400055
Jun 17, 2035method-of-use (U-2427)US 10092525
Jun 17, 2035method-of-use (U-2442)US 10111840
Jun 17, 2035method-of-use (U-2455)US 10137095
Jun 17, 2035method-of-use (U-2783)US 10603288
Jun 17, 2035method-of-use (U-2862)US 10709671
Jun 17, 2035formulationUS 10709673
Jun 17, 2035method-of-use (U-2780)US 10709674
Jun 17, 2035method-of-use (U-2454)US 10849860
Jun 17, 2035formulationUS 10966939
Jun 17, 2035method-of-use (U-3236)US 11154516
Jun 17, 2035method-of-use (U-3376)US 11311498
Jun 17, 2035method-of-use (U-2862)US 11357741
Jun 17, 2035method-of-use (U-3071)US 11446258
Jun 17, 2035formulationUS 11633369
Jun 17, 2035method-of-use (U-2781)US 11701330
Jun 17, 2035method-of-use (U-2781)US 11766411
Jun 17, 2035method-of-use (U-2781)US 11963937
Jun 17, 2035method-of-use (U-3989)US 12064399
Jun 17, 2035method-of-use (U-2421)US 9949937
Jun 17, 2035method-of-use (U-2423)US 9956183
Jun 17, 2035method-of-use (U-2424)US 9956184
Jun 17, 2035method-of-use (U-2425)US 9956185
Jun 17, 2035method-of-use (U-2426)US 9956186

FDA exclusivities (3)

Jul 31, 2027ODE-326Orphan Drug (7y)1.1y
Jul 31, 2027ODE-332Orphan Drug (7y)1.1y
Oct 20, 2026M-270Method (3y)105d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 31m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 3

companyUniversity of Colorado Denver1 co-mentions · 1 sources
companyJohns Hopkins University1 co-mentions · 1 sources
tagPain1 co-mentions · 1 sources

Trials studying cannabidiol

phase4Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solutionactive not recruitingn=154
phase3Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factorsterminatedn=90
phase2Unique Treatment of Oncology Pain in Advanced Cancercompletedn=11
—Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancyrecruitingn=50
phase2Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritisterminatedn=20
phase4A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolexnot yet recruitingn=25
phase4A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complexactive not recruitingn=79
phase3Stratification and Treatment in Early Psychosis Study - PROMOTEnot yet recruitingn=586

more trials →